229 Review of personal hand held record for cystic fibrosis children  by Narayan, O. et al.
Posters 11. Delivery of care S105
227 Detecting early markers of CF-related pulmonary exacerbations
using home telemetry and sputum biomarkers
E.F. Ukor1, J. Ryan1, K. Brown1,2, C.S. Haworth1, K. Auton3, R.A. Floto1,2.
1Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, United
Kingdom; 2Cambridge Institute for Medical Research, Cambridge, United
Kingdom; 3Aseptika Ltd, Huntingdon, United Kingdom
Objectives: Acute pulmonary exacerbations (APE) are the greatest cause of
morbidity in patients with cystic ﬁbrosis (CF). Home based detection and mon-
itoring of APE might ensure prompt initiation of therapy and rapid switching
of ineffective antibiotic regimens that could potentially result in reduced hospital
clinic appointments and admission and better long-term lung health. We therefore
sought to assess whether daily home monitoring of sputum bacterial biomarkers
and clinical parameters might provide advanced warning of infective exacerbations
and/or treatment failure.
Methods: On a daily basis for a 6 month period, 15 adults with CF were asked to
collect sputum samples, undertake home-based telemetric physiological monitoring
(of FEV1, PEF, heart rate, saturations, weight, activity) and complete wellness
and cough diaries. Sputum samples were retrospectively analyzed for levels of
Pseudomonas exotoxin A (PEA) levels and complete data sets were examined to
evaluate which parameters best predicted APE.
Results: Patient compliance with home monitoring was excellent. A number
of combinations of physiological parameters may allow early, pre-symptomatic
detection of APE. In a subgroup of patients, relative changes in PEA may also
predict APE.
Conclusion: Home monitoring was acceptable to patients, provided unprecedented
temporal resolution of clinical parameters and allowed analysis of sputum biomarker
changes preceding an APE and during antibiotic therapy. PEA may prove an
effective biomarker, when combined with other parameters, for early detection of
APEs and treatment failure in patients with CF.
228 Telemedicine videoconferencing − breaking down the barriers for
cystic ﬁbrosis (CF) patients living in rural and remote areas
L. Mitchell1, K. Schultz2, D. Clark1, J.W. Wilson1,3. 1The Alfred Hospital,
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University, Melbourne, Australia; 3Monash University, Melbourne, Australia
Objectives: To use telemedicine to improve access to care for CF patients in
rural settings. We examined 40 patients who have commenced clinic review using
telemedicine videoconferencing (TMVC). Patients living in rural areas were targeted
for participation.
Methods: The TMVC cohort was compared to the non-TMVC CF population at
our institution. A standardised remote area classiﬁcation grading system (Australian
Standard Geographical Classiﬁcation) was used to determine remoteness, classiﬁed
as R1: Major Cities, R2: Inner Cities, R3: Outer Regional and R4/5: Remote/Very
Remote. The Socio-Economic Indexes for Areas (SEIFA) data from the 2011
national census was examined to determine degree of advantage/disadvantage (mean
national value 1000).
Results: 73% of patients receiving TMVC lived >100 km from specialist centre
(mean 197, SD 151), compared to 23% for the general CF population (mean 75km,
SD 151). 15% of TMVC patients were from R3, compared to 4% for the comparison
group. Mean Index of Relative Socio-Economic Advantage and Disadvantage
(IRSAD), and Index of Education and Occupation (IEO) were signiﬁcantly lower
for the TMVC patients than the general CF population; 966 versus 1017 (p< 0.001),
and 968 versus 1037 (p 0.001), indicating greater socioeconomic disadvantage.
Conclusion: TMVC represents an additional means of outpatient assessment and
review. Our institution utilised this technology primarily for patients from rural
and remote areas as an alternative means of medical and allied health assessment.
Access to healthcare for a group of patients from socially disadvantaged areas has
been improved by facilitating specialised outreach using TMVC.
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Background: There is no standardized patient held records for Cystic Fibrosis
(CF) patients in the United Kingdom. After an extensive consultation process with
CF children and families, a Personal Hand Held Record (PHHR) was created. The
PHHR has eight sections that include personal data, allergies, medicine lists, growth
chart, lung function tests, physiotherapy, blood and microbiology results.
Objectives: To ascertain the usefulness of a personal record for patients with Cystic
Fibrosis and their families.
Methods: Young adults and parents were interviewed regarding the usefulness of a
PHHR. A national feedback was also sought online at Cystic Fibrosis Trust website.
There was an universal positivity towards the need of such record. Once the PHHR
was created and rolled on for 1 year, a feedback survey was created. A 15 question
survey was created for CF families to ﬁll and return anonymously.
Results: 82 Patients were sent the survey. 30 patients have returned the survey to
date. 24/30 (80%) found it as extremely useful or useful. Parents whose children
were newly diagnosed children with CF were more likely to use it as they felt
the need of writing down several informations in one place. 24/30 (80%) used it
regularly for the clinic appointments, while 10/30 (33%) used it for holidays as a
useful source of information for emergencies. Comments included: ‘it is a Godsend’
‘this is my memory!’.
Conclusion: A concept of PHHR for any chronic disease is very useful. It gives
the children and parents control of their disease and provides a single point for
recording data and storing documents. This is especially useful when going away
or visiting health care professionals.
230 The development of a new quick/easy CF wellness score (Alfred
Wellness Score for CF, “AweScore-CF”) to improve delivery of
clinical care in the outpatient and inpatient settings suggests
patients acclimatise to low lung function
B.M. Button1,2, A. Guﬂer2,3, D. Clark1, L. Mitchell1, J.W. Wilson1. 1Monash
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A need for a quick/easy wellness scoring tool for use in a large adult CF unit to
improve delivery of care was identiﬁed.
Objectives: To develop a short and simple questionnaire including aspects of daily
life that encompass wellness for routine use across the adult CF population during
baseline state and acute exacerbations.
Methods: With Alfred Ethics Committee approval a 10 item wellness score was
developed using a 1−10 point visual analogue scale (VAS) by members of the
CF multidisciplinary team (MDT). The anchors of the VAS were 1 = least well;
10 = most well. Perfect wellness = 100%. The 10 items were: amount of coughing
in 24 hours; sputum volume; energy levels; exercise participation; appetite; weight;
mood; anxiety; sleep amount/quality; and general health.
Results: A total of 145 patients (70 male) participated, 102 during baseline function
vs 43 during acute exacerbations requiring IV antibiotics. Mean (standard deviation)
and range: age 31.4 (10.2) [19−71] vs 33 (10.3) [21−49] years. FEV1%pred
63.3 (23.1) [22–114] vs 51.1 (19.3) [21–101]. Patients enthusiastically completed
the score in 1−2 minutes. During baseline state those with mild to moderate lung
disease (FEV1 >40%) had mean score 72.4 (13.0) vs those with severe disease
(FEV1 <40%) score of 64.5 (11.4), p = 0.093 ns. The score quickly highlights
problems that require treatment from the MDT and may assist in deciding when to
start and stop therapies.
Conclusion: This well accepted quick/easy tool may improve delivery of care to CF
in the outpatient and inpatient settings. Using this score we conclude that patients
acclimatise to low levels of lung function in advanced disease with reports of
relatively high levels of perceived wellness.
